Cancer Treatment Centers of America In Tulsa Sees Last Patients After Almost 31 Years
After almost 31 years of caring for thousands of patients, Cancer Treatment Centers of America in Tulsa saw its last appointments on May 27.
While most patients have figured out where to continue their care, some employees are still trying to decide what to do next. Not to be emotional,” said Wendy Wheaton, a former patient and employee. “I didn t think I would be, but I kind of feel like I ve grieved and had to move on because I m in active treatment.
Wendy Wheaton worked at the hospital for about 29 years until 2018. In 2017, she was diagnosed with bile duct cancer.
Cancer Treatment Centers of America In Tulsa Sees Last Patients After Almost 31 Years khits.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from khits.com Daily Mail and Mail on Sunday newspapers.
Former CTCA Tulsa Patients Searching For New Cancer Care Options
Patients have been searching for new doctors since Cancer Treatment Centers of America announced it’s closing its Tulsa location a month ago.
Some have found new care, but others are concerned about where to go next. The day they announced they were closing, I started calling everybody to see who could get me in, said Lt. Commander Murry Estabrook.
Estabrook found out he had Stage 4 pancreatic cancer in January and got an appointment with Cancer Treatment Centers of America within 48 hours. After they announced their June closure, he was worried he wouldn t have a place to go.
Former CTCA Tulsa Patients Searching For New Cancer Care Options newson6.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newson6.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Sumanta Pal, MD, a SWOG Cancer Research Network researcher and City of Hope physician, led a study that sets a new standard of care for metastatic papillary kidney cancer view more
Credit: City of Hope
In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice.
These findings will be presented at ASCO s virtual 2021 Genitourinary Cancers Symposium on Feb. 13, 2021 at 1 p.m. ET. The findings will be simultaneously published in